PMP22 and Charcot-Marie-Tooth disease type 1A: Then, targeted gene testing using multiplex ligation-dependent probe amplification (MLPA) was decided upon, which demonstrated a heterozygous pathological duplication of the PMP22 gene, confirming a diagnosis of CMT disease type 1A (CMT1A).